EUVIMEDEUVIMED entdecken
Crossref

[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data

Caroline Boursier iD, Timothée Zaragori, Nicolas Garabedian, Marie Blonski, Tiphaine Obara, Luc Taillandier, Laetitia Imbert, Antoine Verger

European Journal of Nuclear Medicine and Molecular Imaging · 2026-02 · 53 (3) · 2047-2053

DOI: 10.1007/s00259-025-07555-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 22.09.2025. Verfasst von Caroline Boursier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France. c.boursier@chru-nancy.fr. Hauptthemen laut MEDLINE: Meningioma, Organometallic Compounds, Octreotide, Meningeal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. METHODS: Patients with refractory and progressive meningiomas treated with [177Lu]Lu-DOTATATE from 2021 to 2024 were retrospectively included. Association analyses of clinical factors, WHO grade, prior therapy (surgery, radiation, systemic therapy: bevacizumab or a combination of octreotide/everolimus), 3D-MRI volume and pretreatment PET parameters with 6-month progression-free survival (PFS-6), as defined by the 3D-RANO criteria, were performed. Growth rates obtained via MRI and tumor absorbed doses (TAD) were also calculated. RESULTS: Sixteen patients (60 [55;68] years old) underwent 4 [2;4] cycles of [177Lu]Lu-DOTATATE, with a TAD/cycle of 0.45 [0.30;0.83] Gy/GBq/cycle. Only prior systemic therapy was found as a risk factor for PFS-6 (p ≤ 0.05), with an impact on tumor growth rate (TGR) (4 vs. 12 patients, + 125% vs. -107%, p < 0.01). For the 12 patients without any prior systemic therapy, the PFS-6 was 67% (8/12 patients) whereas it was 0% in the other group, those with prior systemic therapy. No associations between the TAD and difference in the TGR before/after SSTR-RT were observed in the overall population (p = 0.10) or in the population of patients without any prior therapy (p = 0.72). CONCLUSION: [177Lu]Lu-DOTATATE appears effective in refractory meningiomas with no prior systemic therapy, even if the TADs are relatively low. [177Lu]Lu-DOTATATE should be proposed as early as possible in the treatment course of refractory meningiomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaOrganometallic CompoundsOctreotideMeningeal NeoplasmsHumansMiddle AgedMaleFemaleAgedRetrospective StudiesTreatment OutcomeRadiometry

Stichwörter der Autor:innen

CZT cameraDosimetryMeningiomaRadionuclide therapy[177Lu]Lu-DOTATATE

Substanzen

Organometallic Compoundslutetium Lu 177 dotatateOctreotide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France. c.boursier@chru-nancy.fr.
  • Université de Lorraine, IADI, INSERM U1254, Nancy, F-54000, France. c.boursier@chru-nancy.fr.
  • Université de Lorraine, IADI, INSERM U1254, Nancy, F-54000, France.
  • CHRU-Nancy, Université de Lorraine, CIC 1433, Innovation Technologique, Inserm, Nancy, F-54000, France.
  • Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France.
  • Department of Neuro-Oncology, Université de Lorraine, CHRU Nancy, Nancy, F-54000, France.

ORCID-Profile: Caroline Boursier

Zitieren

APA

Boursier, C., Zaragori, T., Garabedian, N., Blonski, M., Obara, T., Taillandier, L., Imbert, L., & Verger, A. (2026). [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 2047-2053. https://doi.org/10.1007/s00259-025-07555-x

Vancouver

Boursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, et al. [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(3):2047-2053. doi:10.1007/s00259-025-07555-x

BibTeX
@article{Boursier2026,
  author = {Boursier, Caroline and Zaragori, Timothée and Garabedian, Nicolas and Blonski, Marie and Obara, Tiphaine and Taillandier, Luc and Imbert, Laetitia and Verger, Antoine},
  title = {[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {3},
  pages = {2047--2053},
  doi = {10.1007/s00259-025-07555-x}
}
Kostenlos starten →